Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.
Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki FY, Schwarz TF, Bosch FX, Harper DM, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Szarewski A, et al. Among authors: naud p. Int J Cancer. 2012 Jul 1;131(1):106-16. doi: 10.1002/ijc.26362. Epub 2011 Oct 23. Int J Cancer. 2012. PMID: 21858807 Free article. Clinical Trial.
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Paavonen J, et al. Among authors: naud p. Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Lancet. 2009. PMID: 19586656 Clinical Trial.
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.
Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, Wheeler CM, Salmerón J, Chow SN, Apter D, Teixeira JC, Skinner SR, Hedrick J, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Paavonen J, Bozonnat MC, Descamps D, Struyf F, Dubin GO, Rosillon D, Baril L; HPV PATRICIA Study Group. Jaisamrarn U, et al. Among authors: naud p. PLoS One. 2013 Nov 19;8(11):e79260. doi: 10.1371/journal.pone.0079260. eCollection 2013. PLoS One. 2013. PMID: 24260180 Free PMC article. Clinical Trial.
Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study.
Longatto-Filho A, Erzen M, Branca M, Roteli-Martins C, Naud P, Derchain SF, Hammes L, Sarian LO, Bragança JF, Matos J, Gontijo R, Lima T, Maeda MY, Tatti S, Syrjänen S, Dores G, Lörincz A, Syrjänen K. Longatto-Filho A, et al. Among authors: naud p. Int J Gynecol Cancer. 2006 May-Jun;16(3):955-62. doi: 10.1111/j.1525-1438.2006.00582.x. Int J Gynecol Cancer. 2006. PMID: 16803469
Co-factors of high-risk human papillomavirus infections display unique profiles in incident CIN1, CIN2 and CIN3.
Syrjänen K, Shabalova I, Naud P, Derchain S, Sarian L, Kozachenko V, Zakharchenko S, Roteli-Martins C, Nerovjna R, Longatto-Filho A, Kljukina L, Tatti S, Branovskaja M, Branca M, Grunjberga V, Erzen M, Juschenko A, Hammes LS, Costa S, Podistov J, Syrjänen S; NIS and the LAMS Study Research Groups; Analysis of the combined prospective cohort of the NIS; LAMS Studies. Syrjänen K, et al. Among authors: naud p. Int J STD AIDS. 2011 May;22(5):263-72. doi: 10.1258/ijsa.2009.009280. Int J STD AIDS. 2011. PMID: 21571974
Risk estimates for persistent high-risk human papillomavirus infections as surrogate endpoints of progressive cervical disease critically depend on reference category: analysis of the combined prospective cohort of the New Independent States of the Former Soviet Union and Latin American Screening studies.
Syrjänen K, Shabalova I, Naud P, Kozachenko V, Derchain S, Zakharchenko S, Roteli-Martins C, Nerovjna R, Longatto-Filho A, Kljukina L, Tatti S, Branovskaja M, Hammes LS, Branca M, Grunjberga V, Eržen M, Juschenko A, Costa S, Sarian L, Podistov J, Syrjänen S; NIS and LAMS Study Research Groups. Syrjänen K, et al. Among authors: naud p. Int J STD AIDS. 2011 Jun;22(6):315-23. doi: 10.1258/ijsa.2009.009365. Int J STD AIDS. 2011. PMID: 21680666
Drug addiction is not an independent risk factor for oncogenic human papillomavirus infections or high-grade cervical intraepithelial neoplasia: case-control study nested within the Latin American Screening study cohort.
Syrjänen K, Naud P, Derchain S, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Hammes LS, Matos J, Gontijo R, Sarian L, Bragança J, Arlindo FC, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S. Syrjänen K, et al. Among authors: naud p. Int J STD AIDS. 2008 Apr;19(4):251-8. doi: 10.1258/ijsa.2007.007179. Int J STD AIDS. 2008. PMID: 18482945
Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.
Syrjänen K, Shabalova I, Sarian L, Naud P, Longatto-Filho A, Derchain S, Kozachenko V, Zakharchenko S, Roteli-Martins C, Nerovjna R, Kljukina L, Tatti S, Branovskaja M, Branca M, Grunjberga V, Erzen M, Juschenko A, Serpa Hammes L, Podistov J, Costa S, Syrjänen S; NIS Study Research Group; LAMS Study Research Group. Syrjänen K, et al. Among authors: naud p. Eur J Gynaecol Oncol. 2012;33(1):5-14. Eur J Gynaecol Oncol. 2012. PMID: 22439398
93 results